Skip to main content
. Author manuscript; available in PMC: 2020 Jul 29.
Published in final edited form as: Hum Pathol. 2019 Apr 1;88:66–77. doi: 10.1016/j.humpath.2019.03.004

Table 2.

Genetic differences between salivary duct carcinoma de novo and salivary duct carcinoma ex pleomorphic adenoma.

SDC (N=29) SDCDN (N=15) SDCXPA (N=14) p value
All somatic alterations 230 85 145
  Pathogenic/oncogenic somatic alterations 124 (54%) 63 (74%) 72 (50%) 0.0003
Somatic mutations, median (range) 135, 3 (1-19) 49, 3 (1-6) 85, 4 (1-19)
  Pathogenic/oncogenic somatic mutations 91 (67%) 38 (78%) 53 (62%) NS
CNA, median (range) 91, 1 (0-22) 32, 1 (0-15) 59, 2 (0-22)
  Oncogenic CNA 30 (33%) 11 (34%) 19 (32%) NS
Structural variants (fusion, intragenic deletion) 5 (17%) 4 (27%) 1 (7%)
  Oncogenic structural variants 4 (80%) 3 (75%) 0
TP53 mutations 20 (69%) 6 (40%) 14 (100%) 0.0007
  Missense TP53 mutations 9 (31%) 0 9 (64%) 0.01
ERBB2 amplification 8 (28%) 1 (7%) 7 (50%) 0.01
TP53 mutations + ERBB2 amplification 7 (24%) 0 7 (50%) 0.002

Abbreviations: SDC=salivary duct carcinoma, SDCDN=salivary duct carcinoma de novo, SDCXPA=salivary duct carcinoma ex pleomorphic adenoma.